Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | SLC26A4 | O43511 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25296777 | 1.00 | CASP3 (0.61) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL24470577 | 1.00 | CASP3 (0.61) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL30569371 | 1.00 | CASP3 (0.61) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL24470565 | 0.95 | CASP3 (0.59) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL24470558 | 0.94 | CASP3 (0.63) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL24470587 | 0.93 | SLC26A4 (0.52) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL24470542 | 0.93 | SLC26A4 (0.52) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL29713087 | 0.93 | SLC26A4 (0.52) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL24470852 | 0.93 | CASP3 (0.66) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL29713037 | 0.93 | CASP3 (0.66) | CASP3SENP8SENP7SENP6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | claimed |
| EP-4259613-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2023-10-18 | — | — | EP | claimed |
| WO-2022112345-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | claimed |
| EP-4554577-A1 | NOVEL USE | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024227792-A1 | HUMAN TRPM3 INHIBITORS FOR USE IN THE TREATMENT OF EPILEPSY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024013052-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-01-18 | — | — | WO | disclosed |
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4259613-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2023-10-18 | — | — | EP | disclosed |
| US-20230220037-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| WO-2022112345-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112345-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220037-A1 | NOVEL USE | RAMP3, TRPM7, TRPM4 | CASP3 1162/4885SENP8 1140/4885SENP7 914/4885 |
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPV3, TRPM6, TRPM4 | CASP3 533/4885SENP8 3709/4885SENP7 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.